- Piramal Pharma Solutions has signed a Memorandum of Understanding (MoU) with IntoCell Inc. to explore collaboration opportunities in antibody-drug conjugate (ADC) development.
- The partnership combines Piramal’s contract manufacturing expertise with IntoCell’s proprietary drug-linker technologies to accelerate bioconjugate development.
Piramal Pharma Solutions, a global Contract Development and Manufacturing Organization (CDMO) and subsidiary of Piramal Pharma Ltd., has entered into a Memorandum of Understanding (MoU) with IntoCell Inc., a Korean biotechnology company known for its proprietary ADC linker and payload platform technologies.
Under this non-exclusive, non-binding agreement, IntoCell will explore licensing opportunities for its drug-linker technologies with Piramal’s clients, while Piramal will provide comprehensive contract research, development, and manufacturing services for bioconjugates, including ADCs, to IntoCell and its partners.
The collaboration strengthens Piramal’s existing payload-linker and bioconjugation capabilities, expanding the range of available payload-linkers and enabling faster bioconjugate development timelines. Key technologies included in the agreement are IntoCell’s OHPAS linker, Duocarmycin-based OHPAS-payload, Nexatecan-based OHPAS-payload, and iso-Nexatecan-based GGFG-payload.
The partnership also enhances ADCelerate™, Piramal’s integrated bioconjugate development platform, by leveraging IntoCell’s technologies to streamline the journey from concept to clinic.
“We are pleased to collaborate with Piramal Pharma Solutions, a leading CDMO. We will do our utmost to ensure the mutual success of both companies by combining our respective areas of expertise.”
Tae Kyo Park, CEO of IntoCell
“By combining IntoCell’s groundbreaking drug-linker technologies with our extensive expertise in bioconjugates, we position ourselves as the ideal partner for clients innovating in this critical segment.”
Peter DeYoung, CEO of Piramal Global Pharma
